Lydisilka Unione Europea - estone - EMA (European Medicines Agency)

lydisilka

estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - suguhormoonid ja genitaalsüsteemi, - suukaudne kontratseptsioon. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Unione Europea - estone - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroksabaan - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombootilised ained - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Okedi Unione Europea - estone - EMA (European Medicines Agency)

okedi

laboratorios farmacéuticos rovi, s.a. - risperidone - skisofreenia - psühhoeptikumid - treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

Sunlenca Unione Europea - estone - EMA (European Medicines Agency)

sunlenca

gilead sciences ireland unlimited company - lenacapavir sodium - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 ja 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 ja 5.

Leqvio Unione Europea - estone - EMA (European Medicines Agency)

leqvio

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipiidi modifitseerivad ained - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

BETAHISTINE SANDOZ tablett Estonia - estone - Ravimiamet

betahistine sandoz tablett

sandoz pharmaceuticals d.d. - beetahistiin - tablett - 8mg 50tk; 8mg 40tk; 8mg 60tk; 8mg 90tk; 8mg 100tk; 8mg 80tk; 8mg 30tk; 8mg 10tk; 8mg 20tk

BETAHISTINE SANDOZ tablett Estonia - estone - Ravimiamet

betahistine sandoz tablett

sandoz pharmaceuticals d.d. - beetahistiin - tablett - 24mg 20tk; 24mg 60tk; 24mg 100tk; 24mg 120tk; 24mg 30tk; 24mg 10tk; 24mg 80tk; 24mg 40tk; 24mg 50tk

BETAHISTINE SANDOZ tablett Estonia - estone - Ravimiamet

betahistine sandoz tablett

sandoz pharmaceuticals d.d. - beetahistiin - tablett - 16mg 80tk; 16mg 40tk; 16mg 90tk; 16mg 120tk; 16mg 10tk; 16mg 100tk; 16mg 20tk; 16mg 30tk; 16mg 60tk

BETAHISTINE ACTAVIS tablett Estonia - estone - Ravimiamet

betahistine actavis tablett

teva b.v. - beetahistiin - tablett - 16mg 84tk; 16mg 60tk; 16mg 50tk; 16mg 20tk

BETAHISTINE ACCORD tablett Estonia - estone - Ravimiamet

betahistine accord tablett

accord healthcare b.v. - beetahistiin - tablett - 24mg 90tk; 24mg 20tk; 24mg 60tk; 24mg 84tk; 24mg 50tk; 24mg 100tk